Commissioner Stephen Hahn said Thursday the Food and Drug Administration is moving at “lightning speed” to review all data on Gilead’s experimental Covid-19 treatment, remdesivir. His remarks came after encouraging results emerged from a key U.S. trial.
In a recent interview, Hahn was quoted as saying, “We’re working with the company to emphasize the necessity of speed while at the same time to understand the data. He added, “There will be a lot of factors that go into all the regulatory decisions. We want to look at the totality of data to make sure that remdesivir is targeted to the right patients.”
SEE MORE: BLOOMBERG.COM